decor-right

Our Unique Story

Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. Gritstone’s approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. We believe that activating and directing the immune system to these tumor targets could offer an important opportunity to extend the benefits of immunotherapy for patients with cancer. To learn more about Gritstone's approach, please view the video below.

Meet Gritstone:

Gritstone Oncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts and Pleasanton, California. We were founded in August 2015 and are listed on the Nasdaq Global Select Market under the ticker symbol GRTS.

Our Leadership

To deliver on the promise of our novel therapeutic approach, we have assembled an experienced leadership team with deep expertise in each of our core disciplines of cancer genomics, immunology, clinical and regulatory development and biomanufacturing.

View Bio
Andrew Allen, M.D., Ph.D.

Co-founder, President and Chief Executive Officer

View Bio
Jean-Marc Bellemin, M.B.A.

Executive Vice President and Chief Financial Officer

View Bio
Matthew Hawryluk, Ph.D.

Executive Vice President and Chief Business Officer

View Bio
Erin E. Jones, M.S.

Executive Vice President, Global Regulatory Affairs and Quality

View Bio
Karin Jooss, Ph.D.

Executive Vice President of Research and Chief Scientific Officer

View Bio
Raphaël F. Rousseau, M.D., Ph.D.

Executive Vice President and Chief Medical Officer

View Bio
Roman Yelensky, Ph.D.

Executive Vice President and Chief Technology Officer

Board
of Directors

Andrew Allen, M.D., Ph.D.
Co-founder, President and Chief Executive Officer
Richard A. Heyman, Ph.D.
Executive Chairman and co-founder of Metacrine
Judith J. Li
Partner at Lilly Asia Ventues (LAV)
Steve Krognes
Chief Financial Officer of Denali Therapeutics
Nicholas Simon
Managing Director of Clarus Ventures
Peter Svennilson
Founder of The Column Group (TCG)
Tom Woiwode, Ph.D.
Managing Director at Versant Ventures

Scientific
Advisory Board

Timothy A. Chan, M.D. Ph. D
Mark Cobbold, M.D., Ph.D.
James L. Gulley, M.D., Ph.D.
Graham Lord, M.D., Ph.D.
Naiyer A. Rizvi, M.D.
Alessandro Sette, Dr.Biol.Sci.
Top